Biocon
BIOCON
Biocon Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 26,44,644 |
| Weekly | 11.67% | 1,08,75,717 |
| Monthly | 8.81% | 5,35,67,108 |
Biocon Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| BIOCON | - | 11.67% | 8.81% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
Biocon Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| BIOCON | 264.24 | 4.95 | 15.58 | 6.78 | 5.84 | 0.20 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Biocon Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 0.13% | -31.79% | 6.78% | 5.84% |
| FY '20-21 | 3.12% | -16.76% | 8.42% | 7.98% |
| FY '19-20 | -5.13% | -10.34% | 10.17% | 10.99% |
Biocon Shareholding Pattern
Biocon Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 4,961.10 | 4,183.65 | 1,215.60 | 532.30 |
| FY '20-21 | 4,585.75 | 3,779.10 | 1,185 | 603.05 |
| FY '19-20 | 4,242.35 | 3,466.45 | 1,131.95 | 670.35 |
Biocon Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| BIOCON | 4,961.10 | 4,183.65 | 1,215.60 | 532.30 |
| AUROPHARMA | 17,371.31 | 14,451.27 | 3,425.76 | 2,066.53 |
| LUPIN | 14,088.58 | 13,878.47 | 427.52 | -849.21 |
Biocon Share Price
Biocon Limited is an Indian biopharmaceutical company focused on the treatment of diabetes, cancer and autoimmune diseases. Its segment includes generics, similar biologics, novel biologics and research services. It has developed and commercialised novel biologics, biosimilars and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as generic formulations in the US, Europe and key emerging markets. Its API portfolio includes cardiology, diabetes, immunosuppressants, multiple sclerosis, cancer/oncology and other key products. Its products include tacrolimus, rosuvastatin, simvastatin, atorvastatin, pravastatin, fingolimod and others. It has more than five locations in Bangalore, Hyderabad and Visakhapatnam in India. Its API production facilities use sophisticated technology platforms ranging from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.